Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2026-05-26 16:06:23 ET · period of report 2026-05-21 · accession 0001291963-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 16:06 | 2026-05-21 | KPTI | Greene Barry E | Dir | A - Grant | $0.00 | +15.5K | 16.4K | +1,710% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-21 | A | A | 15,508 | $0.00 | 16,415 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. (F2) Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025. |